VolitionRx (NYSEAMERICAN:VNRX – Get Rating) was downgraded by stock analysts at Benchmark from a "buy" rating to a "hold" rating in a note issued to investors on Wednesday, Marketbeat reports. The analysts noted that the move was a valuation call.
Separately, EF Hutton Acquisition Co. I began coverage on shares of VolitionRx in a research report on Monday, December 19th. They issued a "buy" rating and a $6.00 target price for the company.
Get VolitionRx alerts:VolitionRx Stock Performance
Shares of NYSEAMERICAN:VNRX opened at $2.35 on Wednesday. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.04 and a quick ratio of 1.04. The company has a market capitalization of $134.66 million, a P/E ratio of -4.12 and a beta of 1.73. VolitionRx has a 52 week low of $1.31 and a 52 week high of $3.30.
VolitionRx (NYSEAMERICAN:VNRX – Get Rating) last issued its quarterly earnings results on Monday, November 14th. The medical research company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.05 million. VolitionRx had a negative net margin of 15,452.74% and a negative return on equity of 350.45%. As a group, analysts expect that VolitionRx will post -0.59 earnings per share for the current fiscal year.Insider Activity at VolitionRx
In related news, Director Martin Charles Faulkes bought 55,000 shares of the company's stock in a transaction on Friday, December 16th. The stock was bought at an average cost of $2.10 per share, with a total value of $115,500.00. Following the completion of the purchase, the director now owns 1,637,068 shares in the company, valued at approximately $3,437,842.80. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, insider Jacob Vincent Micallef acquired 25,000 shares of the firm's stock in a transaction that occurred on Monday, December 19th. The stock was purchased at an average price of $2.30 per share, for a total transaction of $57,500.00. Following the completion of the acquisition, the insider now owns 188,392 shares in the company, valued at $433,301.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Martin Charles Faulkes acquired 55,000 shares of the firm's stock in a transaction that occurred on Friday, December 16th. The shares were purchased at an average price of $2.10 per share, with a total value of $115,500.00. Following the acquisition, the director now owns 1,637,068 shares of the company's stock, valued at approximately $3,437,842.80. The disclosure for this purchase can be found here. Insiders bought 106,489 shares of company stock valued at $228,812 in the last ninety days. Insiders own 16.00% of the company's stock.
Hedge Funds Weigh In On VolitionRx
Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. raised its holdings in VolitionRx by 1.0% in the 1st quarter. BlackRock Inc. now owns 547,862 shares of the medical research company's stock valued at $1,650,000 after buying an additional 5,644 shares during the last quarter. State Street Corp grew its position in shares of VolitionRx by 10.0% during the 1st quarter. State Street Corp now owns 115,323 shares of the medical research company's stock worth $347,000 after buying an additional 10,500 shares during the period. Captrust Financial Advisors grew its position in shares of VolitionRx by 316.7% during the 1st quarter. Captrust Financial Advisors now owns 25,000 shares of the medical research company's stock worth $75,000 after buying an additional 19,000 shares during the period. Cowen Prime Advisors LLC grew its position in shares of VolitionRx by 83.2% during the 4th quarter. Cowen Prime Advisors LLC now owns 177,043 shares of the medical research company's stock worth $430,000 after buying an additional 80,412 shares during the period. Finally, Spectrum Asset Management Inc. NB CA acquired a new stake in shares of VolitionRx during the 4th quarter worth approximately $135,000. 10.30% of the stock is currently owned by institutional investors and hedge funds.
VolitionRx Company Profile
(Get Rating)
VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.
Further Reading
- Get a free copy of the StockNews.com research report on VolitionRx (VNRX)
- Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
- Mullen Automotive Stock Gains Momentum On Positive News
- Harley-Davidson Inc. Stock, Is It Time To Buy?
- The Bottom Is In For Meta Platforms, Volatility Is Not Over
- Analyzing Alaska Air's Recent Earnings
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.